Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

8:01 AM ET 8-K
Nasdaq/NYSE Compliance Notice SurgePays, Inc. SURG

SurgePays Nasdaq/NYSE Compliance Notice

SurgePays received an additional 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement, extending the deadline to March 22, 2027. Separately, Nasdaq confirmed the company has regained compliance with the minimum stockholders' equity requirement. The company intends to cure the bid price deficiency by effecting a reverse stock split if necessary.

Counterparty
The Nasdaq Stock Market LLC
Term
until March 22, 2027
7:46 AM ET 8-K
M&A Deal Soundthinking, Inc. SSTI

Soundthinking Signs $114M M&A Deal with Transom Capital Group, LLC

SoundThinking, Inc. has entered into a definitive agreement to be acquired by Transom Capital Group via a tender offer for $8.00 per share in cash plus a contingent value right (CVR) worth up to $3.00. The deal implies an upfront enterprise value of approximately $114 million, representing a 46% premium to the company's prior closing price, and will result in SoundThinking becoming a private company.

Value
$114M
Counterparty
Transom Capital Group, LLC
7:36 AM ET 8-K
Clinical Trial Data Cartesian Therapeutics, Inc. RNAC

Cartesian Therapeutics Clinical Trial Data

Cartesian Therapeutics announced positive 12-month retreatment data from its Phase 2 trial of Descartes-08 in patients with myasthenia gravis (MG). The data showed that patients who were retreated after symptom recurrence experienced deep and durable responses, with a mean MG-ADL score reduction of 6.6 points at 12 months and no new safety signals. Topline data from the Phase 3 AURORA trial is expected in the first quarter of 2027.

7:27 AM ET 8-K
Clinical Trial Data Invivyd, Inc. IVVD

Invivyd Clinical Trial Data

Invivyd announced positive topline results from its LIBERTY Phase 3 study, which demonstrated that its COVID-19 monoclonal antibody candidate, VYD2311, had safety and tolerability superior to an mRNA-based vaccine. The company plans to use data from LIBERTY and the ongoing DECLARATION pivotal study to support a Biologics License Application (BLA) submission to the FDA via the Accelerated Approval Program.

Earnings call
Sep 29, 2026, 8:30 AM ET
7:06 AM ET 8-K
Divestiture 1 800 Flowers Com Inc FLWS

1 800 Flowers Com Divestiture to PlanetArt, LLC for $45M

1-800-FLOWERS.COM, Inc. has entered into a definitive agreement to sell its Personalization Businesses, including PersonalizationMall.com and Things Remembered, to PlanetArt, LLC for $45 million in cash. The divestiture is intended to sharpen the company's portfolio focus on its primary brands and strengthen its financial position for strategic growth initiatives. The parties also plan to enter into a commercial agreement allowing 1-800-FLOWERS.COM to continue offering select personalized products to its customers post-closing.

Value
$45M
Counterparty
PlanetArt, LLC
7:04 AM ET 8-K
Divestiture BeyondSpring Inc. BYSI

BeyondSpring Divestiture to Biolin Investment Limited

BeyondSpring entered into a definitive agreement to sell its majority equity interest in its Chinese subsidiary, Bulin, to Biolin Investment Limited. In exchange for the equity, the investor will fund and conduct the China portion of the global Phase 3 DUBLIN-4 trial for Plinabulin, which is expected to cover approximately 50% of the total trial enrollment.

Counterparty
Biolin Investment Limited
Term
3 years
Earnings call
Sep 29, 2026, 8:00 AM ET
7:01 AM ET 8-K
M&A Deal CID Holdco, Inc. DAIC

CID Holdco Signs $65M M&A Deal with Envoy Technologies, Inc.

CID HoldCo, Inc. entered into a definitive Securities Purchase Agreement to acquire 100% of Envoy Technologies, Inc. from BladeRanger Ltd. for $65 million in stock. The consideration consists of approximately 10.8 million shares of common and Series C preferred stock valued at a reference price of $6.00 per share, including shares allocated to settle a $12.5 million convertible note.

Value
$65M
Counterparty
Envoy Technologies, Inc.
7:00 AM ET 8-K
Clinical Trial Data Immix Biopharma, Inc. IMMX

Immix Biopharma Clinical Trial Data

Immix Biopharma announced positive interim results from its Phase 2 NEXICART-2 clinical trial of NXC-201 in relapsed/refractory AL Amyloidosis, showing an 89% complete response rate across 45 patients. The company noted that MRD-negativity predicts future complete responses, potentially increasing the rate to 98%, and plans a BLA submission for the therapy in mid-2027.

Earnings call
Sep 29, 2026, 8:00 AM ET
6:30 AM ET 8-K
Clinical Trial Data Alzamend Neuro, Inc. ALZN

Alzamend Neuro Clinical Trial Data

Alzamend Neuro presented Phase 1/2A clinical trial data for AL001, a novel organic lithium salt, at the ISMRT Conference. The study utilized 7T MRI imaging to evaluate brain pharmacokinetics, demonstrating that AL001 is designed for improved brain delivery with lower systemic exposure compared to standard inorganic lithium salts.

Counterparty
Massachusetts General Hospital
6:05 AM ET 8-K
M&A Deal Stewards, Inc. SWRD

Stewards Signs $90M M&A Deal with Envy Development DE, LLC and Envy Recreational, LLC

Stewards, Inc. completed the acquisition of Envy Development DE, LLC and Envy Recreational, LLC, which own the real estate assets of Envy Pompano Beach, for an aggregate purchase price of $90.0 million. The consideration consisted of $44.6 million in refinanced debt, $42.8 million in common stock (14,263,025 shares), and a $2.0 million unsecured promissory note. A portion of the shares (7 million) were placed in escrow to be redeemed for cash payments of $3.0 million monthly starting in October 2026.

Value
$90M
Counterparty
Envy Development DE, LLC and Envy Recreational, LLC
6:05 AM ET 8-K
Capital Raise Summit Therapeutics Inc. SMMT

Summit Therapeutics Capital Raise of $2B

Summit Therapeutics entered into a securities purchase agreement with AstraZeneca for a $2.0 billion private placement of newly designated Class A Convertible Preferred Stock. The preferred shares are priced at a common stock equivalent of $18.3561 per share and will be used to support the development of ivonescimab, including new clinical collaborations with AstraZeneca's oncology portfolio.

Value
$2B
Counterparty
AstraZeneca Holdings B.V.

“This significant investment, as well as the collaboration, is a powerful validation of the potential of ivonescimab. We are proud to welcome AstraZeneca as a strategic investor as we continue to work with purposeful urgency to make a significant difference for patients with cancer by improving outcomes.”

Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit Therapeutics

“The developments announced today with AstraZeneca open an exciting new chapter in the advancement of ivonescimab. With a growing body of evidence supporting ivonescimab’s differentiated PD-1 / VEGF bispecific approach, we look forward to further broadening the development plan of ivonescimab and initiating new clinical trials exploring the potential to combine ivonescimab with promising novel anti-cancer compounds, including ADCs, to bring together complementary approaches to tumor-cell killing, antitumor immunity, and the tumor microenvironment.”

Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics
6:05 AM ET 8-K
M&A Deal OpenWorld, Inc. OPNW

VerifyMe M&A Deal with Open World Ltd.

VerifyMe, Inc. provided a status update on its pending merger with Open World Ltd. by filing required pro forma financial information and audited financial statements for the target company as requested by Nasdaq. The transaction, originally announced in February 2026, involves Open World becoming a wholly owned subsidiary of VerifyMe.

Counterparty
Open World Ltd.
6:04 AM ET 8-K
M&A Deal Futurewave Acquisition Corp FWAC

Futurewave Acquisition Signs $400M M&A Deal with Olympian Group Inc.

Futurewave Acquisition Corporation (FWAC), a SPAC, has entered into a definitive merger agreement to acquire Olympian Group Inc., a Hong Kong-based provider of integrated chip and electronic component solutions. The transaction values Olympian at an agreed net value of $400 million, with Olympian shareholders receiving 40 million shares of the combined company at $10.00 per share. Upon closing, the combined entity is expected to remain listed on the Nasdaq Stock Market.

Value
$400M
Counterparty
Olympian Group Inc.
6:04 AM ET 8-K
M&A Deal Aar Corp AIR

Aar Signs $2.6B M&A Deal with MRO Holdings, Inc.

AAR CORP. has entered into a definitive agreement to acquire a 65% controlling interest in MRO Holdings for approximately $2.6 billion in cash and preferred stock. The deal creates the world's largest heavy maintenance MRO provider, adding over $1 billion in annual revenue and significantly expanding AAR's EBITDA margins. The transaction is expected to close in the third fiscal quarter ending February 2027.

Value
$2.6B
Counterparty
MRO Holdings, Inc.

“Through the acquisition of MRO Holdings, we will create the largest heavy maintenance MRO in the world, servicing a combined total of nearly 3,000 aircraft per year in our hangars. As a result of this scale, we expect to drive additional volume through our Component MRO facilities, we will have a much larger channel for new and existing OEM distribution relationships, and we will have additional avenues for data collection supporting our software business.”

John M. Holmes, Chairman, President and CEO of AAR

“The transaction structure allows us to partner with a proven team that brings decades of experience in a strategically important region. This structure also provides the financial flexibility to continue to pursue AAR’s broader strategy. This highly strategic acquisition is truly transformational for AAR and marks a significant step in our long-term growth plan.”

John M. Holmes, Chairman, President and CEO of AAR
6:01 AM ET 8-K
Nasdaq/NYSE Compliance Notice Bayview Acquisition Corp BAYA

Bayview Acquisition Nasdaq/NYSE Compliance Notice

Bayview Acquisition Corp received notice that the Nasdaq Listing and Hearing Review Council affirmed a prior decision to delist the company's securities. The delisting stems from the company's failure to complete its business combination with Oabay Inc. by the June 19, 2026 deadline. The company intends to transition the listing of its ordinary shares and rights to the OTC Pink Market.

Counterparty
Nasdaq
6:01 AM ET 8-K
M&A Deal FF EAI Robotics Ecosystem Inc. FFR

AIxCrypto Holdings M&A Deal with Faraday Future Intelligent Electric Inc.

AIxCrypto Holdings, Inc. entered into a non-binding term sheet to acquire the robotics business (RobotCo) from its majority stockholder, Faraday Future Intelligent Electric Inc. (FFAI). The proposed transaction is being reviewed by a Special Committee of independent directors due to its related-party nature and remains subject to the negotiation of definitive agreements and a fairness opinion.

Counterparty
Faraday Future Intelligent Electric Inc. (FFAI)
6:00 AM ET 8-K
Divestiture National Healthcare Properties, Inc. NHP

National Healthcare Properties Divestiture to unaffiliated third party for $531M

National Healthcare Properties, Inc. announced that certain termination rights have expired under a purchase and sale agreement to sell its portfolio of 40 outpatient medical facilities for approximately $531 million. The transaction is expected to close in the fourth quarter of 2026, subject to customary closing conditions.

Value
$531M
Counterparty
unaffiliated third party
5:33 PM ET 8-K
M&A Deal Clearway Energy LLC

Clearway Energy Signs $230M M&A Deal with Swan CE Seller LLC

Clearway Energy LLC's subsidiary, Swan Purchaser LLC, entered into a definitive agreement to acquire membership interests in Swan TargetCo LLC for approximately $230 million. The target company will indirectly own Swan Solar LLC, which is developing a 650-megawatt solar facility in Bates County, Missouri. The transaction is expected to close in the third quarter of 2028.

Value
$230M
Counterparty
Swan CE Seller LLC
Term
through Q3 2028
5:33 PM ET 8-K
M&A Deal Clearway Energy, Inc. CWEN

Clearway Energy Signs $230M M&A Deal with Swan CE Seller LLC

Clearway Energy, through its subsidiary Swan Purchaser LLC, has entered into a definitive agreement to acquire membership interests in Swan TargetCo LLC for approximately $230 million in cash. The target company will indirectly own Swan Solar LLC, which is developing a 650-megawatt solar facility in Bates County, Missouri. The transaction is expected to close in the third quarter of 2028, subject to customary conditions.

Value
$230M
Counterparty
Swan CE Seller LLC
5:28 PM ET 8-K
Capital Raise Viking Therapeutics, Inc. VKTX

Viking Therapeutics Capital Raise of $316M

Viking Therapeutics closed a public equity offering of 9,035,714 shares of common stock at $35.00 per share, including the full exercise of the underwriters' overallotment option. The company raised approximately $297.0 million in net proceeds from the equity portion. Simultaneously, the company issued $258.75 million in 2.00% Convertible Senior Notes due 2032 to further strengthen its balance sheet.

Value
$316M
Counterparty
Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC
5:21 PM ET 8-K/A
M&A Deal Kodiak Gas Services, Inc. KGS

Kodiak Gas Services M&A Deal with Distributed Power Solutions, LLC

Kodiak Gas Services, Inc. filed an amendment to provide pro forma financial information regarding its previously completed acquisition of Distributed Power Solutions, LLC (DPS). The filing includes unaudited pro forma condensed combined statements of operations for the six months ended June 30, 2026, treating the acquisition as if it had occurred on January 1, 2025.

Counterparty
Distributed Power Solutions, LLC
5:16 PM ET 8-K
Nasdaq/NYSE Compliance Notice Nexalin Technology, Inc. NXL

Nexalin Technology Nasdaq/NYSE Compliance Notice

Nexalin Technology received a notification from the Nasdaq Hearings Panel granting a conditional extension to regain compliance with listing standards. The company must demonstrate a minimum bid price of $1.00 for 20 consecutive trading sessions by September 28, 2026, and meet the $2.5 million stockholders' equity requirement by January 4, 2027.

Counterparty
Nasdaq
5:09 PM ET 8-K
Divestiture Faraday Future Intelligent Electric Inc. FFAI

Faraday Future Intelligent Electric Divestiture to AIxCrypto Holdings, Inc for $200M

Faraday Future Intelligent Electric Inc. entered into a non-binding term sheet to sell its robotics business to its majority-owned subsidiary, AIxCrypto Holdings, Inc., for $200 million. The consideration will be paid in AIxC common and non-voting convertible preferred stock, and the transaction is being reviewed by a Special Committee of the Board due to its related-party nature.

Value
$200M
Counterparty
AIxCrypto Holdings, Inc
4:56 PM ET 8-K
M&A Deal NorthStar Earth & Space Enterprises, Inc. NSTR

Viking Acquisition Corp I M&A Deal with NorthStar Earth & Space Inc.

Viking Acquisition Corp. I (VACI) announced that its previously disclosed business combination with NorthStar Earth & Space Inc. is expected to close on September 30, 2026. Following the merger, the combined company will be renamed NorthStar Earth & Space Enterprises, Inc. and will transfer its listing to the NYSE American under the ticker 'NSTR' on October 1, 2026.

Counterparty
NorthStar Earth & Space Inc.
4:44 PM ET 8-K
Capital Raise Greenland Mines Ltd GRML

Greenland Mines Capital Raise of $17.2M

Greenland Mines Ltd. entered into a securities purchase agreement with institutional investors to issue 1,320,000 shares of common stock in a direct registered offering. The company expects to receive approximately $17.2 million in net proceeds to fund its Greenland mining operations and general working capital. Additionally, the company terminated its previously established $50 million at-the-market offering program with A.G.P./Alliance Global Partners.

Value
$17.2M
Counterparty
institutional investors
4:42 PM ET 8-K
Nasdaq/NYSE Compliance Notice SilverBox Corp IV SBXDF

SilverBox Corp IV Nasdaq/NYSE Compliance Notice

SilverBox Corp IV announced that its units, Class A ordinary shares, and warrants have been delisted from the New York Stock Exchange effective September 28, 2026. The securities have transitioned to the OTCID Basic Market and are now trading under the new ticker symbols SBXUF, SBXDF, and SBXWF, respectively.

Counterparty
New York Stock Exchange LLC
4:38 PM ET 8-K
M&A Deal Mccormick & Co Inc MKC

Mccormick & Co M&A Deal with Unilever PLC

McCormick & Company provided a status update on its pending acquisition of Unilever's foods business, noting that the deal's anticipated closing will cause its current auditor, Ernst & Young LLP, to lose independence. Consequently, the company has appointed KPMG LLP as its new independent registered public accounting firm effective for the fiscal year ending November 30, 2027.

Counterparty
Unilever PLC
4:36 PM ET 8-K
Divestiture Keurig Dr Pepper Inc. KDP

Keurig Dr Pepper Divestiture to Chobani for $925M

Keurig Dr Pepper completed the divestiture of its indirect equity interests in Chobani and the sale of certain assets, including leasehold interests in two Pennsylvania facilities, to Chobani. The total consideration of $925 million consists of $525 million in cash and an $800 million promissory note maturing in December 2026. This transaction represents a full exit from the company's investment in Chobani alongside an asset disposal.

Value
$925M
Counterparty
Chobani
4:31 PM ET 8-K
M&A Deal Isabella Bank Corp ISBA

Isabella Bank Signs $18.3M M&A Deal with Grand River Commerce, Inc.

Isabella Bank Corporation provided a status update on its pending acquisition of Grand River Commerce, Inc., announcing the mailing of election materials to shareholders. Grand River shareholders have until October 23, 2026, to elect to receive cash (estimated at $5.71 per share) or Isabella common stock (estimated exchange ratio of 0.1413) as merger consideration.

Value
$18.3M
Counterparty
Grand River Commerce, Inc.
4:31 PM ET 8-K
Divestiture Cambium Networks Corp CMBMF

Cambium Networks Divestiture to Airspan Communications Limited for $27.5M

Cambium Networks Corporation's subsidiary, Cambium Networks, Ltd (in administration), completed the sale of its defense business and certain fixed broadband product lines to Airspan Communications Limited for $27.5 million in cash. The deal includes a contingent earn-out of up to $7.5 million based on accounts receivable collections and involves transitional services and licensing agreements. The company does not expect to retain any net proceeds as the funds will be applied toward the subsidiary's administration and secured credit facility obligations.

Value
$27.5M
Counterparty
Airspan Communications Limited

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.